Evogliptin Set For First Launch, In Crowded Korean Market
This article was originally published in PharmAsia News
Dong-A ST's new type 2 diabetes therapy Suganon (evogliptin) has been approved in South Korea where it is set to compete with a number of already marketed DPP-4 inhibitors in an increasingly crowded sector. The domestic approval follows global licensing out deals for the drug in the past few years in other markets including China, India, Brazil and Russia.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.